BioXcel: Navigating The Peaks And Valleys Of Regulatory Uncertainties (NASDAQ:BTAI)

Blue Capsules on Conveyor at Modern Pharmaceutical Factory. Tablet and Capsule Manufacturing Process. Close-up Shot of Medical Drug Production Line.


Thesis revisit, still maintaining a hold rating

FDA Investigation and Stock Implications

Recently, BioXcel Therapeutics (NASDAQ:BTAI) has faced regulatory scrutiny with the FDA’s ongoing investigation related to the conduct of one of the TRANQUILITY II study’s primary

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *